Serina Therapeutics, Inc. financial data

Symbol
SER on NYSE
Industry
Pharmaceutical Preparations
Location
601 Genome Way, Suite 2001, Huntsville, AL
State of incorporation
AL
Fiscal year end
December 31
Former names
AgeX Therapeutics, Inc. (to 4/1/2024)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 68 % +196%
Debt-to-equity -206 % -221%
Return On Equity 76.7 %
Return On Assets -125 % -372%
Operating Margin -30.4K % -30576%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.93M shares +297%
Common Stock, Shares, Outstanding 9.42M shares +291%
Entity Public Float 38.4M USD +105%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 7.36M shares +229%
Weighted Average Number of Shares Outstanding, Diluted 7.36M shares +0.11%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 56K USD -98.2%
Cost of Revenue 40K USD +208%
Research and Development Expense 7.48M USD +213%
General and Administrative Expense 9.62M USD +147%
Operating Income (Loss) -17M USD -445%
Nonoperating Income (Expense) 5.84M USD -30.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -11.1M USD -311%
Earnings Per Share, Basic -1.51 USD/shares -164%
Earnings Per Share, Diluted -1.51 USD/shares -307%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.67M USD -51.8%
Accounts Receivable, after Allowance for Credit Loss, Current 65K USD +983%
Other Assets, Current 77K USD
Assets, Current 5.68M USD -25.5%
Property, Plant and Equipment, Net 501K USD -12.6%
Operating Lease, Right-of-Use Asset 461K USD -30.8%
Intangible Assets, Net (Excluding Goodwill) 509K USD -20.5%
Assets 6.72M USD -25%
Accounts Payable, Current 744K USD +28.3%
Accrued Liabilities, Current 1.43M USD +145%
Liabilities, Current 2.37M USD +67.4%
Operating Lease, Liability, Noncurrent 268K USD -41.9%
Liabilities 6.22M USD +28%
Retained Earnings (Accumulated Deficit) -44.3M USD -33.6%
Stockholders' Equity Attributable to Parent 641K USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 508K USD
Liabilities and Equity 6.72M USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.58M USD -122%
Net Cash Provided by (Used in) Financing Activities 2.73M USD -73%
Net Cash Provided by (Used in) Investing Activities -14K USD +99.9%
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 9.42M shares +291%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.14M USD -87.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD -92.9%
Deferred Tax Assets, Valuation Allowance 35.4M USD +176%
Deferred Tax Assets, Gross 35.7M USD +175%
Operating Lease, Liability 460K USD -31.9%
Depreciation 24K USD +33.3%
Payments to Acquire Property, Plant, and Equipment 14K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -11.1M USD -19.4%
Lessee, Operating Lease, Liability, to be Paid 503K USD
Property, Plant and Equipment, Gross 1.1M USD +14.4%
Operating Lease, Liability, Current 192K USD -10.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 159K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 217K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 43K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 117K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.5M USD +121%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 816K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 10K USD
Operating Lease, Payments 55K USD +25%
Additional Paid in Capital 45M USD +4992%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 101K USD -22.9%
Deferred Tax Assets, Net of Valuation Allowance 226K USD +61.4%
Share-based Payment Arrangement, Expense 2.6M USD +10280%
Interest Expense 4.91M USD +72.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%